Council Bluffs, Iowa Clinical Trials

A listing of Council Bluffs, Iowa clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Dupilumab Asthma Sleep Study

Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: To evaluate the effect of dupilumab on additional patient reported sleep outcomes To evaluate the effect of dupilumab on objective sleep assessment To evaluate the effect of dupilumab on asthma symptoms To evaluate the effect of dupilumab on …

polysomnography
forced expiratory volume
leukotriene receptor antagonist
eosinophil count
fractional exhaled nitric oxide
Investigational Site Number 8400010
 (9.7 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +10 other locations
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

pd-l1
erbb1
drug test
solid tumor
growth factor
University of Nebraska Medical Center /ID# 216754
 (5.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +38 other locations
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

hras gene
recurrent thyroid gland carcinoma
donor lymphocyte infusion
HRAS
nitrosoureas
University of Nebraska Medical Center
 (5.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +82 other locations
PTI-125 100 mg for Mild-to-moderate Alzheimer's Disease Patients

An Open-label study for patients who completed the previous studies, PTI-125-02 or PTI-125-03. Additional new patients will be included for a total of 100 patients enrolled for this study.

positron emission tomography
rivastigmine
dementia
amyloidosis
amyloid
Cognitive Clinical Trials
 (5.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +8 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

eliglustat
imiglucerase
gaucher disease
deficiency
Investigational Site Number 840084
 (5.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +220 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840084
 (5.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +135 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

myozyme
replacement therapy
glycogen storage disease type ii
gaa gene
deficiency
Investigational Site Number 840084
 (5.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +190 other locations
Fabry Disease Registry & Pregnancy Sub-registry

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary …

agalsidase beta
alpha-galactosidase
replacement therapy
fabrazyme
fabry's disease
Investigational Site Number 840084
 (5.6 away) Contact site
  • 0 views
  • 05 Aug, 2024
  • +136 other locations
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying research data and samples from patients who experience immunotherapy side effects may help researchers better understand how to predict, prevent, and treat these side effects.

biospecimen collection
Creighton University Medical Center
 (5.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +380 other locations
Pharmacokinetics Pharmacodynamics and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to …

SARS
acute respiratory syndrome (sars)
University of Nebraska Medical Center
 (9.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +34 other locations